Nascent Biotech Inc. (NBIO)
Stock Price:
$0.0650 USD
0.0010 (1.56%)
Updated Oct 16, 2020 2:23 PM EDT - Market closed
Key Info
| Market Cap |
4.20M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-3.93M |
| Shares Out |
64.56M |
| EPS (ttm) |
-0.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 16, 2020 |
| Last Price |
$0.0650 |
| Previous Close |
$0.0640 |
| Change ($) |
0.0010 |
| Change (%) |
1.56% |
| Day's Open |
0.0650 |
| Day's Range |
0.0610 - 0.0650 |
| Day's Volume |
87,182 |
| 52-Week Range |
0.057 - 0.35 |
More Stats
| Market Cap |
4.20M |
| Enterprise Value |
4.46M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
64.56M |
| Float |
36.48M |
| EPS (basic) |
-0.11 |
| EPS (diluted) |
-0.10 |
| FCF / Share |
-0.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
-1.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.91 |
| Revenue |
n/a |
| Operating Income |
-3.70M |
| Net Income |
-3.93M |
| Free Cash Flow |
-479,946 |
| Net Cash |
-260,818 |
| Net Cash / Share |
0.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-80,140.20% |
| ROE |
n/a |
| ROIC |
266.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | 3.00 | - | - | - | - |
| Gross Profit | - | - | - | 3.00 | - | - | - | - |
| Operating Income | -3.45 | -1.37 | -2.22 | 0.95 | -3.87 | -2.14 | -0.57 | -0.67 |
| Net Income | -4.00 | -1.37 | -2.22 | 1.14 | -4.15 | -2.15 | -1.92 | -0.69 |
| Shares Outstanding | 34.39 | 30.09 | 25.88 | 21.80 | 19.77 | 13.99 | 3.15 | 2.69 |
| Earnings Per Share | -0.12 | -0.05 | -0.09 | 0.05 | -0.21 | -0.15 | -0.61 | -0.26 |
| Operating Cash Flow | -0.55 | -0.71 | -1.22 | -0.77 | -0.17 | -0.47 | -0.13 | -0.09 |
| Free Cash Flow | -0.55 | -0.71 | -1.22 | -0.77 | -0.17 | -0.47 | -0.13 | -0.09 |
| Cash & Equivalents | 0.00 | 0.13 | 0.12 | 0.13 | 0.57 | 0.11 | 0.11 | 0.00 |
| Total Debt | 0.14 | - | - | - | - | 0.06 | - | 0.15 |
| Net Cash / Debt | -0.14 | 0.13 | 0.12 | 0.13 | 0.57 | 0.05 | 0.11 | -0.15 |
| Assets | - | 0.13 | 0.12 | 0.90 | 1.40 | 0.94 | 0.12 | 0.01 |
| Liabilities | 2.88 | 0.61 | 0.20 | 0.17 | 2.97 | 3.14 | 1.57 | 1.95 |
| Book Value | -2.88 | -0.48 | -0.09 | 0.73 | -1.57 | -2.21 | -1.45 | -1.95 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Nascent Biotech Inc. |
| Country |
United States |
| CEO |
Sean Carrick |
Stock Information
| Ticker Symbol |
NBIO |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: NBIO |
Description
Nascent Biotech, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company has a research collaboration agreement with Manhattan BioSolutions, Inc. to initiate a vaccine program for the prevention of COVID-19 or other viral infections; and a collaboration with Hoag Family Cancer Institute and Pickup Family Neurosciences Institute for the testing of antibody brain cancer drug. The company is based in San Diego, California.